# 乳腺癌核心针活检市场 > 乳腺癌核心针活检市场研究报告，按目标组织（乳腺、前列腺、肺、肝、肾）、按针头尺寸（14号、16号、18号、20号、22号）、按方式（超声引导、立体定向、其他）、按程序类型（门诊、住院）、按活检设备类型（真空辅助、弹簧加载、重力供给）以及按地区（北美、欧洲、南美、亚太、中东和非洲） - 预测到2035年 - **Forecast Period:** 2025 - 2035 - **CAGR:** 5.25% - **2024:** $ 0.4 Billion - **2025:** $ 0.42 Billion - **2035:** $ 0.7 Billion - **Key Players:** Hologic (US), BD (US), Siemens Healthineers (DE), GE Healthcare (US), Philips (NL), Canon Medical Systems (JP), Fujifilm (JP), Medtronic (IE), Stryker (US) **Report ID:** MRFR/HC/27391-HCR · **Pages:** 128 · **Author:** Rahul Gotadki · **Last Updated:** April 06, 2026 **URL:** https://www.marketresearchfuture.com/reports/breast-cancer-core-needle-biopsy-market-29097 --- ## Market Summary ## **Breast Cancer Core Needle Biopsy Market Overview** As per MRFR analysis, the Breast Cancer Core Needle Biopsy Market Size was estimated at 0.38 (USD Billion) in 2023. The Breast Cancer Core Needle Biopsy Market Industry is expected to grow from 0.4 (USD Billion) in 2024 to 0.59 (USD Billion) by 2032. The Breast Cancer Core Needle Biopsy Market CAGR (growth rate) is expected to be around 5.25% during the forecast period (2024 - 2032). ## **Key Breast Cancer Core Needle Biopsy Market Trends Highlighted** The rising incidence of breast cancer, growing awareness of early detection techniques, and technological advancements in core needle biopsy drive the global breast cancer core needle biopsy market. Minimally invasive procedures, improved diagnostic accuracy, and increasing healthcare expenditure further contribute to market growth. Trends in recent times include the adoption of vacuum-assisted breast biopsy (VABB) for improved sample collection, advancements in ultrasound-guided core needle biopsy (US-CNB) for real-time visualization, and the emergence of automated core needle biopsy devices for enhanced precision and accuracy. Opportunities for market expansion exist in developing regions with limited access to advanced healthcare facilities, the integration of artificial intelligence (AI) for better image analysis, and the development of molecular biomarkers to guide treatment decisions. Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review ## **Breast Cancer Core Needle Biopsy Market Drivers** ### Increasing Prevalence of Breast Cancer Breast cancer is the most common cancer among women worldwide, with an estimated 2.3 million new cases and 685,000 deaths in 2020. The rising incidence of breast cancer is primarily attributed to factors such as increasing age, lifestyle changes, and environmental factors. As the population ages, the risk of developing breast cancer increases. Additionally, lifestyle factors such as obesity, lack of physical activity, and unhealthy diets have been linked to an increased risk of breast cancer. Environmental factors, such as exposure to certain chemicals and radiation, have also been implicated in the development of breast cancer. The increasing prevalence of breast cancer has led to a growing demand for diagnostic procedures, including core needle biopsies. Core needle biopsies are minimally invasive procedures that allow physicians to obtain tissue samples from the breast for examination under a microscope. This helps in the accurate diagnosis of breast cancer and in determining the appropriate course of treatment. The Global Breast Cancer Core Needle Biopsy Market Industry is expected to witness significant growth over the forecast period due to the rising incidence of breast cancer and the increasing adoption of core needle biopsies as a diagnostic tool. ### Technological Advancements Technological advancements have significantly improved the accuracy and efficiency of core needle biopsies. The development of new imaging techniques, such as ultrasound and MRI-guided biopsies, has allowed physicians to target specific areas of the breast with greater precision. Additionally, the introduction of automated core needle biopsy systems has streamlined the procedure, reducing the time and discomfort associated with the biopsy. Technological advancements have also led to the development of new biopsy devices with smaller needles and improved sampling capabilities. These devices minimize tissue damage and provide high-quality tissue samples for analysis. The availability of advanced biopsy devices has contributed to the growing adoption of core needle biopsies in the diagnosis of breast cancer. ### Rising Awareness and Early Detection Initiatives Increased awareness about breast cancer and the importance of early detection have contributed to the growth of the Global Breast Cancer Core Needle Biopsy Market Industry. Government and healthcare organizations have implemented various initiatives to promote breast cancer awareness and encourage women to undergo regular screening. These initiatives have led to an increase in the number of women seeking diagnostic procedures, including core needle biopsies. Early detection of breast cancer is crucial for successful treatment and improved patient outcomes. Core needle biopsies play a vital role in the early detection of breast cancer by providing accurate and timely diagnosis. The growing emphasis on early detection and the increasing awareness about breast cancer are expected to drive the demand for core needle biopsies in the coming years. ## **Breast Cancer Core Needle Biopsy Market Segment Insights** ### **Breast Cancer Core Needle Biopsy Market Target Tissue Insights** The Global Breast Cancer Core Needle Biopsy Market is segmented into various segments including Target Tissue. Target Tissue is categorizing the market into Breast, Prostate, Lung, Liver, Kidney and others. Among them, Breast segment held the largest share of the market in 2023. The high prevalence of breast cancer and the increasing adoption of core needle biopsies for breast cancer diagnosis are major factors driving the growth of this segment. The increasing awareness of breast cancer and the importance of early detection are also contributing to the growth of the Breast segment. The Prostate segment is also expected to witness significant growth over the forecast period. The increasing incidence of prostate cancer and the growing adoption of core needle biopsies for prostate cancer diagnosis are major factors driving the growth of this segment. The Lung segment is expected to grow at a moderate rate during the forecast period due to the rising incidence of lung cancer and the increasing adoption of core needle biopsies for lung cancer diagnosis. The Liver segment is expected to grow at a steady pace over the forecast period. The Kidney segment is expected to grow at a moderate rate due to the rising incidence of kidney cancer and the increasing adoption of core needle biopsies for kidney cancer diagnosis. Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review ### **Breast Cancer Core Needle Biopsy Market Needle Size Insights** The Global Breast Cancer Core Needle Biopsy Market is segmented by needle size, with options including 14-Gauge, 16-Gauge, 18-Gauge, 20-Gauge, and 22-Gauge. Among these, the 14-Gauge needle segment holds a significant market share due to its ability to provide larger tissue samples, leading to more accurate diagnoses. The 16-Gauge and 18-Gauge needle segments follow closely, offering a balance between sample size and patient comfort. The 20-Gauge and 22-Gauge needle segments are preferred for less invasive procedures and are gaining traction in outpatient settings. The Global Breast Cancer Core Needle Biopsy Market revenue is expected to witness substantial growth in the coming years, driven by factors such as increasing breast cancer incidence, technological advancements, and rising healthcare expenditure. ### **Breast Cancer Core Needle Biopsy Market Modality Insights** The Global Breast Cancer Core Needle Biopsy Market segmentation by Modality includes Ultrasound-Guided, Stereotactic, and Other. Ultrasound-Guided segment held the largest market share of 42.1% in 2023 and is expected to continue its dominance throughout the forecast period. The increasing adoption of ultrasound-guided core needle biopsy due to its accuracy, real-time visualization, and cost-effectiveness contributes to its market dominance. The stereotactic segment is projected to witness a significant growth rate of 8.2% during the forecast period, owing to the rising demand for minimally invasive procedures and technological advancements in stereotactic systems. Other segments, which includes MRI-guided and vacuum-assisted core needle biopsy, is expected to grow steadily due to the expanding applications and improved accuracy of these techniques. ### **Breast Cancer Core Needle Biopsy Market Procedure Type Insights** The Global Breast Cancer Core Needle Biopsy Market is segmented by Procedure Type into Outpatient and Inpatient. Outpatient procedures account for a larger share of the market due to the increasing adoption of minimally invasive procedures and the convenience it offers to patients. The rising number of outpatient surgery centers and the growing preference for same-day surgeries further contribute to the growth of this segment. Inpatient procedures, on the other hand, are preferred for complex cases that require specialized equipment or extended monitoring. Despite the growing popularity of outpatient procedures, inpatient procedures are expected to maintain a steady share in the market due to the need for specialized care in certain cases. The Global Breast Cancer Core Needle Biopsy Market revenue from Outpatient procedures is projected to reach 2.65 billion USD by 2024. ### **Breast Cancer Core Needle Biopsy Market Biopsy Device Type Insights** The Global Breast Cancer Core Needle Biopsy Market is segmented by Biopsy Device Type into Vacuum-Assisted, Spring-Loaded, and Gravity-Fed. By 2024, the Vacuum-Assisted segment is projected to have a dominant market share, driven by the advantages it offers, including accurate tissue sampling, ease of use, and reduced patient discomfort. Spring-Loaded devices are anticipated to hold a notable market share due to their precision and reliability in obtaining tissue samples. Gravity-Fed devices, while holding a smaller market share, are expected to witness steady growth due to their cost-effectiveness and simplicity of use. The Global Breast Cancer Core Needle Biopsy Market is expected to grow significantly in the coming years, with increasing awareness about early detection and diagnosis of breast cancer, technological advancements, and supportive government initiatives. ### **Breast Cancer Core Needle Biopsy Market Regional Insights** The Global Breast Cancer Core Needle Biopsy Market is segmented into North America, Europe, Asia Pacific, South America, and Middle East Africa. North America is expected to hold the largest market share in 2023, owing to the high prevalence of breast cancer and the increasing adoption of core needle biopsy procedures. Europe is expected to be the second-largest market, followed by Asia Pacific. The Asia Pacific region is expected to witness the fastest growth rate during the forecast period, due to the rising incidence of breast cancer and the increasing awareness of core needle biopsy procedures. South America and Middle East Africa are expected to contribute a smaller share to the global market. Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review ### **Breast Cancer Core Needle Biopsy Market Key Players and Competitive Insights** Major players in the Breast Cancer Core Needle Biopsy Market industry are continuously investing in research and development to enhance their product offerings and expand their market share. Leading Breast Cancer Core Needle Biopsy Market players are focused on developing innovative technologies and solutions to meet the evolving needs of healthcare professionals and patients. The Breast Cancer Core Needle Biopsy Market development is driven by the increasing prevalence of breast cancer, advancements in medical imaging technologies, and the growing demand for minimally invasive procedures. Hologic, Inc. is a leading player in the Breast Cancer Core Needle Biopsy Market industry. The company offers a comprehensive portfolio of breast biopsy systems and devices, including the Affirm Prone Breast Biopsy System, the Mammotome Revolve Biopsy System, and the ProCore Automated Breast Biopsy System. Hologic, Inc. has a strong presence in both the US and international markets and is continuously investing in research and development to enhance its product offerings and expand its market share. BD (Becton, Dickinson and Company) is another major player in the Breast Cancer Core Needle Biopsy Market industry. The company offers a wide range of biopsy systems and devices, including the Bard Magnum Core Biopsy Instrument, the Bard Max-Core Biopsy Instrument, and the Bard Precisio Core Biopsy Instrument. BD (Becton, Dickinson and Company) has a global presence and is focused on developing innovative technologies and solutions to meet the evolving needs of healthcare professionals and patients. ## **Key Companies in the Breast Cancer Core Needle Biopsy Market Include** ## **Breast Cancer Core Needle Biopsy Market Industry Developments** The increasing incidence of breast cancer, technological advancements in biopsy devices, and rising awareness about early detection are key factors driving market growth. Recent developments include the launch of automated core needle biopsy systems and AI-powered image analysis software, enhancing accuracy and efficiency. Key players in the market include Becton, Dickinson and Company, Hologic, Inc., and Cook Medical. ## **Breast Cancer Core Needle Biopsy Market Segmentation Insights** ## Market Drivers ### 关注个性化医学 个性化医疗的转变正在重塑乳腺癌核心针活检市场。随着治疗方案越来越多地针对个体患者的特征进行定制，精确和准确的活检需求变得至关重要。核心针活检提供了关于肿瘤特征的重要信息，这有助于制定个性化的治疗计划。市场预计将看到对促进靶向治疗的活检需求的增加，因为医疗服务提供者旨在优化患者的治疗结果。最近的研究表明，个性化方法可以将治疗效果提高多达40%，从而推动对与这一趋势相一致的先进活检技术的需求。 ### 乳腺癌发病率上升 全球乳腺癌发病率的上升是乳腺癌核心针活检市场的一个关键驱动因素。随着确诊病例数量的持续增长，对有效诊断工具（包括核心针活检）的需求预计也将相应上升。目前的统计数据显示，乳腺癌仍然是最常见的癌症之一，每年报告的新病例数以百万计。这一令人担忧的趋势迫切需要实施有效的诊断方法，以促进早期发现和治疗。因此，随着医疗系统适应乳腺癌日益增加的负担，市场有望增长，确保为活检程序分配足够的资源。 ### 提高意识和筛查程序 近年来，人们对乳腺癌及早期发现的重要性有了显著的认识。乳腺癌核心针活检市场从这一趋势中受益匪浅，因为越来越多的女性参与筛查项目。健康组织的教育活动和倡议促进了筛查率的提高，这反过来又导致了对核心针活检的需求增加。数据显示，拥有强大筛查项目的地区，活检程序增加了25%。这种提高的意识预计将持续推动市场增长，因为越来越多的人寻求及时的诊断和治疗。 ### 活检技术的技术进步 乳腺癌核心针活检市场正在经历技术进步的激增，这些进步提高了活检程序的精确性和效率。超声引导活检和自动化活检系统等创新正变得越来越普遍。这些技术不仅提高了组织取样的准确性，还减少了患者的不适感和恢复时间。根据最近的数据，先进成像技术的采用使成功活检结果增加了30%。随着医疗服务提供者继续投资于最先进的设备，市场可能会扩大，推动这一市场的是对能够提供可靠诊断结果的微创程序的需求。 ### 监管支持和报销政策 支持性的监管框架和有利的报销政策在乳腺癌核心针活检市场中发挥着关键作用。各国政府和卫生当局越来越认识到早期诊断在改善患者结果方面的重要性，这导致了促进使用核心针活检的指南的建立。此外，覆盖这些程序相关费用的报销政策鼓励医疗服务提供者更广泛地采用这些程序。最近的数据表明，拥有全面报销计划的地区活检利用率增加了20%。这种监管支持可能会通过使核心针活检对患者更易获得而促进市场增长。 ## Future Outlook 乳腺癌核心针活检市场预计将在2024年至2035年间以5.25%的年均增长率增长，推动因素包括技术进步、意识提高和发病率上升。 **New opportunities:** - 开发基于人工智能的诊断工具以提高准确性 到2035年，市场预计将实现显著增长，反映出不断变化的医疗保健需求。 ## Segment Insights ### 按靶组织：乳腺（最大）与前列腺（生长最快） 乳腺癌核心针活检市场展示了各类目标组织之间市场份额的明显分布，其中乳腺活检占据了显著的领先地位。这主要是由于全球女性乳腺癌的高发病率， necessitating 频繁的诊断程序。在乳腺细分市场之后，前列腺市场细分也很重要，但在份额规模上仍然落后，说明活检程序中存在多样的临床偏好。 乳腺（主导）与前列腺（新兴） 乳腺部分在乳腺癌核心针活检市场中脱颖而出，成为主导力量，主要是由于需要早期诊断和管理的庞大患者群体。该程序因其安全性和有效性而被广泛接受，进一步推动了该领域的投资。相反，前列腺部分正在迅速崛起，受到意识提升、技术进步和前列腺癌检测率增加的推动。尽管尚未达到乳腺活检的同一规模，但核心针活检技术的创新使前列腺程序变得更加可行，预计在未来几年将获得动力。 ### 按针头大小：16号（最大）与18号（增长最快） 在乳腺癌核心针活检市场中，针头尺寸的分布显示出对16号针头的显著偏好，因为它们在效率和减少患者不适之间保持了良好的平衡。紧随其后的是18号针头，因其能够提供足够的组织样本同时最小化侵入性而越来越受到青睐。其余的尺寸，包括14号、20号和22号针头，占据了较小的市场份额，服务于特定患者群体和临床环境中的小众应用。 针头规格：16号（主流）与18号（新兴） 16号针头已被确立为乳腺癌核心针活检市场的主导选择。其较大的直径有助于提取足够的组织样本，这对准确的诊断结果至关重要。医疗提供者青睐这种尺寸，因为它在各种临床环境中的可靠性和有效性。相比之下，18号针头作为一种备受欢迎的替代品正在崛起，特别是因其在尺寸和患者舒适度之间的适当平衡而受到关注。由于临床医生希望在确保高质量活检结果的同时尽量减少创伤，这种规格正在迅速增长。值得注意的是，临床实践向更少侵入性技术的转变使得18号针头在这一市场中前景广阔。 ### 按方式：超声引导（最大）与立体定向（增长最快） 在乳腺癌核心针活检市场中，超声引导的方式占据了最大的市场份额，主要由于其在临床环境中的有效性和可及性。这种方法结合了实时成像与精确度，从而提高了活检取样的准确性。立体定向程序也在逐渐受到关注，吸引那些希望在最大限度提高诊断准确性的同时减少患者不适的医疗机构。总的来说，这些方式共同促进了一个不断发展的格局，医疗提供者越来越倾向于选择图像引导技术进行乳腺活检。 方式：超声引导（主导）与立体定向（新兴） 超声引导活检已成为乳腺癌核心针活检市场的主导方法，因为它的直观使用和即时成像结果增强了诊断信心。由于其安全性和侵入性较小，成为临床医生的常见选择。相反，立体定向方法被归类为新兴趋势，利用先进的成像技术准确定位乳腺中的病变。这种模式正在快速普及，受到技术进步和日益重视改善患者结果的推动，标志着乳腺癌诊断中整合创新的转变。 ### 按程序类型：门诊（最大）与住院（增长最快） 在乳腺癌核心针活检市场中，手术类型细分主要以门诊手术为特征，门诊手术因其成本效益和患者便利性而主导市场。门诊手术占据了更大的市场份额，因为它们能够提供高效的护理，而无需过夜住院，从而吸引了更广泛的寻求可及性和缩短治疗时间的患者人群。相反，住院手术虽然市场份额较小，但正在迅速获得关注，反映出对需要在活检后进行更密切监测的复杂病例的全面护理的不断演变的偏好。该细分市场的增长趋势显示出向门诊手术的转变，这一转变受到微创技术进步和患者舒适度提高的推动。乳腺癌的意识和早期发现的增加，加上对降低医疗成本的日益关注，正在推动这一趋势。相比之下，住院手术细分市场正在上升，原因是对出现并发症或需要额外干预的病例的转诊增加，表明对能够更好地满足患者需求的高质量、综合护理的需求。 程序类型：门诊（主导）与住院（新兴） 乳腺癌核心针活检市场的门诊部分在患者和医疗提供者中脱颖而出，成为主流选择，主要是由于其结构化的便利性和高效性。患者受益于简化的流程，通常减少了与漫长住院相关的压力。该部分强调门诊设施在进行复杂程序方面的能力，同时使患者能够在同一天返回家中，从而促进积极的患者体验。另一方面，住院部分正在成为复杂病例的必要替代方案，这些病例需要更广泛的监测和术后护理。随着医疗技术的进步，住院程序正在适应以纳入创新解决方案，增强恢复，显示出由医疗机构对全面患者管理的关注所推动的潜在增长。 ### 按活检设备类型：真空辅助（最大）与弹簧加载（增长最快） 乳腺癌核心针活检市场展现出多样化的设备类型分布。真空辅助设备目前占据最大的市场份额，因其高效性和能够提取更大组织样本的能力而受到青睐，从而提供全面的诊断数据。相比之下，弹簧加载设备因其易用性和微创性而获得了关注，吸引了临床医生和患者的青睐。重力供给设备虽然已经建立，但在市场中占据较小的份额，因为它们在复杂程序中不太受欢迎。 真空辅助（主导）与弹簧加载（新兴） 真空辅助活检设备在乳腺癌核心针活检市场中占据主导地位，提供了显著的优势，如更大的样本获取和更高的精确度，增强了诊断能力。这些设备在需要更大组织样本的复杂病例中尤为受欢迎。另一方面，弹簧加载设备在市场中迅速崛起。其用户友好的设计和更快的程序时间正在推动其在各种临床环境中的采用。这一趋势反映了向简化活检过程的设备转变，同时确保患者的舒适。这些技术的独特特性满足了医疗服务提供者和患者不断变化的需求。 ## Regional Market Share Analysis ### 北美：引领创新与需求 北美是乳腺癌核心针活检的最大市场，约占全球市场份额的45%。该地区受益于先进的医疗基础设施、高度的乳腺癌筛查意识和支持性的监管框架。乳腺癌发病率的增加和对微创手术的需求是主要的增长驱动因素。此外，政府倡导早期检测的举措预计将进一步推动市场增长。美国是该地区的领先国家，主要企业如Hologic、BD和GE Healthcare做出了重要贡献。竞争格局以持续创新和主要公司之间的战略合作为特征。先进医疗设施的存在以及对研发的强烈关注进一步增强了市场动态，使北美成为乳腺癌诊断技术的中心。 ### 欧洲：新兴的监管框架 欧洲是乳腺癌核心针活检的第二大市场，约占全球市场份额的30%。该地区由于对乳腺癌筛查的认识提高和活检技术的进步而正在增长。监管机构积极推动早期检测和治疗的指导方针，预计将推动需求。德国和英国等国在市场中处于领先地位，得益于有利的医疗政策和对癌症研究的资金支持。德国在欧洲市场中脱颖而出，主要企业如西门子医疗和飞利浦做出了重要贡献。竞争格局以成熟企业和专注于创新解决方案的新兴初创公司相结合为特征。强大的医疗系统和对患者护理的高度重视进一步增强了市场的增长潜力，使欧洲成为乳腺癌诊断的重要地区。 ### 亚太地区：快速增长的市场潜力 亚太地区在乳腺癌核心针活检市场中是一个新兴的强国，约占全球市场份额的20%。该地区由于乳腺癌发病率的增加、医疗支出的上升和对早期检测的认识提高而经历快速增长。中国和印度等国对先进诊断技术的需求显著增加，政府倡导改善癌症护理和筛查项目。中国在该地区的市场中处于领先地位，越来越多的医疗设施采用创新的活检技术。竞争格局正在演变，本地和国际企业如佳能医疗系统和富士胶卷正在扩大其市场份额。对医疗基础设施的持续投资以及对研发的关注预计将进一步推动亚太地区的市场增长，使其成为未来机会的关键领域。 ### 中东和非洲：未开发的市场机会 中东和非洲代表了乳腺癌核心针活检的未开发市场，约占全球市场份额的5%。该地区逐渐认识到早期检测和治疗乳腺癌的重要性，受到意识提高和医疗倡议的推动。政府改善医疗服务的努力和对癌症研究的资金支持预计将催化市场增长。南非和阿联酋等国在采用先进诊断技术方面走在前列。南非是该地区的关键参与者，越来越多的医疗设施投资于创新的活检解决方案。竞争格局以本地和国际公司相结合为特征，专注于扩大其产品供应。关键参与者的存在以及对患者护理和早期检测的日益重视预计将推动中东和非洲的市场增长，为利益相关者提供重大机会。 ## Competitive Benchmarking 乳腺癌核心针活检市场的特点是动态的竞争格局，受到技术进步和对早期检测与诊断日益重视的推动。主要参与者如Hologic（美国）、BD（美国）和西门子医疗（德国）处于前沿，各自采取不同的策略以增强市场存在感。Hologic（美国）专注于成像技术的创新，而BD（美国）则强调通过战略合作伙伴关系扩展其产品组合。西门子医疗（德国）利用数字化转型来提高诊断准确性，共同塑造了一个优先考虑技术优势和以患者为中心解决方案的竞争环境。 在商业策略方面，公司越来越多地本地化制造，以降低成本并提高供应链效率。市场似乎适度分散，多个参与者争夺市场份额。然而，像GE医疗（美国）和飞利浦（荷兰）等大公司的集体影响力显著，因为它们通过战略合作和并购来巩固其地位。这种竞争结构促进了一个创新和运营效率至关重要的环境。 2025年8月，Hologic（美国）宣布推出一款新的先进成像系统，旨在提高核心针活检的精确度。这一战略举措具有重要意义，因为它不仅强化了Hologic对创新的承诺，还使公司能够通过满足对准确诊断工具日益增长的需求来获取更大的市场份额。这项技术的引入可能会改善患者的治疗结果并简化临床工作流程。 2025年9月，BD（美国）扩大了与一家领先医疗服务提供商的合作伙伴关系，以增强其活检产品在北美的分销。这一举措强调了BD通过协作努力加强市场存在感的战略，这可能会导致其创新解决方案的可及性提高。在一个竞争激烈的环境中，这种合作关系至关重要，因为分销效率可以显著影响市场渗透率。 2025年7月，西门子医疗（德国）推出了一款新的人工智能驱动的分析平台，旨在优化活检程序。这一举措反映了将人工智能整合到医疗保健中的日益趋势，可能会彻底改变活检的执行和分析方式。通过投资于人工智能技术，西门子医疗（德国）将自己定位为诊断过程数字化转型的领导者，这可能增强其竞争优势。 截至2025年10月，乳腺癌核心针活检市场正在见证数字化、可持续性和人工智能整合等趋势。关键参与者之间的战略联盟正日益塑造竞争格局，促进创新并增强运营能力。展望未来，预计竞争差异化将演变，从基于价格的竞争转向对技术创新、供应链可靠性和先进诊断解决方案开发的关注。 ## Recent News & Developments 乳腺癌发病率的增加、活检设备的技术进步以及对早期检测的日益关注是推动市场增长的关键因素。 最近的发展包括自动化核心针活检系统和人工智能驱动的图像分析软件的推出，提高了准确性和效率。市场上的主要参与者包括贝克顿、迪金森公司、霍洛吉克公司和库克医疗。 ## Report Scope | 2024年市场规模 | 0.4（十亿美元） | | --- | --- | | 2025年市场规模 | 0.421（十亿美元） | | 2035年市场规模 | 0.7024（十亿美元） | | 复合年增长率（CAGR） | 5.25%（2024 - 2035） | | 报告覆盖范围 | 收入预测、竞争格局、增长因素和趋势 | | 基准年 | 2024 | | 市场预测期 | 2025 - 2035 | | 历史数据 | 2019 - 2024 | | 市场预测单位 | 十亿美元 | | 主要公司简介 | 市场分析进行中 | | 覆盖的细分市场 | 市场细分分析进行中 | | 主要市场机会 | 微创技术的进步提高了乳腺癌核心针活检市场的诊断准确性。 | | 主要市场动态 | 技术进步和监管变化推动乳腺癌核心针活检市场的创新和竞争。 | | 覆盖的国家 | 北美、欧洲、亚太、南美、中东和非洲 | ## Frequently Asked Questions **Q: 到2035年，乳腺癌核心针活检市场的预计市场估值是多少？** A: 预计到2035年，乳腺癌核心针活检市场的市场估值为7.024亿美元。 **Q: 2024年乳腺癌核心针活检市场的市场估值是多少？** A: 2024年乳腺癌核心针活检市场的市场估值为4亿美元。 **Q: 2025年至2035年，乳腺癌核心针活检市场的预期CAGR是多少？** A: 在2025年至2035年的预测期内，乳腺癌核心针活检市场的预期CAGR为5.25%。 **Q: 在乳腺癌核心针活检市场中，哪些公司被视为关键参与者？** A: 乳腺癌核心针活检市场的主要参与者包括霍洛吉克、BD、西门子医疗、GE医疗、飞利浦、佳能医疗系统、富士胶卷、美敦力和斯特莱克。 **Q: 2024年，乳腺癌核心针活检市场哪个细分领域的估值最高？** A: 在2024年，乳腺癌的靶组织细分市场估值最高，达到2亿美元。 **Q: 2024年14号针头细分市场的估值与20号细分市场相比如何？** A: 在2024年，14号针的市场价值为1亿美元，而20号针的市场价值为0.5亿美元。 **Q: 到2035年，超声引导模式细分市场的预计增长是多少？** A: 超声引导模式细分预计将从2024年的1.6亿美元增长到2035年的约2.816亿美元。 **Q: 在乳腺癌核心针活检市场中，门诊手术的预期市场表现如何？** A: 门诊程序部分预计将从2024年的2.4亿美元增长到2035年的约4.224亿美元。 --- *This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/breast-cancer-core-needle-biopsy-market-29097*